Claims for Patent: 9,655,956

Summary for Patent: 9,655,956

Title:	Chimeric nucleic acid molecules with non-AUG translation initiation sequences and uses thereof
Abstract:	The present disclosure relates to nucleic acid vaccine compositions and methods for preventing or treating pathological conditions, such as cancer or infectious disease. Further, the disclosure provides methods for more efficient production of antigens via mRNA containing one or more non-conventional start codons to promote multiplex initiation of translation in eukaryotic cells.
Inventor(s):	Florkiewicz; Robert Z. (Seattle, WA)
Assignee:	TapImmune Inc. (Jacksonville, FL)
Application Number:	15/222,619
Patent Claims:	1. A chimeric nucleic acid molecule, comprising a multiplex translation initiation (MTI) sequence comprising from two to about five translation initiation sites operatively linked in frame to a nucleic acid molecule encoding a fusion protein comprising from two to about ten human epidermal growth factor receptor 2 (HER2) antigenic peptides, wherein at least one of the MTI translation initiation sites is a non-AUG translation initiation site and the MTI allows the production of more than one mole of fusion protein per mole of mRNA. 2. The chimeric nucleic acid molecule of claim 1, wherein the MTI comprises one, two, three, or four non-AUG translation initiation sites. 3. The chimeric nucleic acid molecule of claim 2, wherein the non-AUG translation initiation sites are CUG translation initiation sites. 4. The chimeric nucleic acid molecule of claim 3, wherein the MTI comprises an AUG translation initiation site downstream of the CUG translation initiation sites. 5. The chimeric nucleic acid molecule of claim 1, wherein the MTI comprises (a) a nucleic acid molecule encoding one or two nuclear localization domains located downstream of two or three CUG translation initiation sites and upstream of an AUG translation initiation site, or (b) two or three CUG translation initiation sites upstream of a nucleic acid molecule encoding one or two nuclear localization domains and no AUG translation initiation site. 6. The chimeric nucleic acid molecule of claim 1, wherein the MTI comprises a 5'-portion of a human FGF2 gene, wherein the 5'-portion of the human FGF2 gene contains an AUG translation initiation site and about 123 nucleotides to about 385 nucleotides upstream of the AUG translation initiation site that is in frame with the nucleic acid molecule encoding the fusion protein. 7. The chimeric nucleic acid molecule of claim 6, wherein the MTI further comprises from about 15 nucleotides to about 45 nucleotides downstream of the AUG translation initiation site. 8. The chimeric nucleic acid molecule of claim 6, wherein the 5'-portion of the human FGF2 gene encodes a polypeptide having at least 90% sequence identity to any one of the amino acid sequences set forth in SEQ ID NOS.:8-12, or encodes a polypeptide as set forth in any one of SEQ ID NOS.:8-12. 9. The chimeric nucleic acid molecule of claim 1, wherein the MTI sequence has at least 90% sequence identity to a nucleotide sequence as set forth in any one of SEQ ID NOS.:1-6, 95, or 96. 10. The chimeric nucleic acid molecule of claim 1, wherein the encoded fusion protein comprises from two to about five different or same antigenic HER2 peptides, or the encoded fusion protein comprises five different antigenic HER2 peptides. 11. The chimeric nucleic acid molecule of claim 1, wherein one or more of the antigenic peptides are an HLA Class I antigenic HER2 peptide, an HLA Class II antigenic HER2 peptide, an HLA Class II antigenic HER2 peptide comprising an embedded HLA Class I antigenic HER2 peptide, or any combination thereof. 12. The chimeric nucleic acid molecule of claim 1, wherein one or more of the encoded HER2 antigenic peptides of the fusion protein comprise on the N-terminus and/or C-terminus: (a) from one to about ten junction amino acids; (b) a spacer comprising from two to about 35 amino acids; (c) a spacer comprising a (Gly.sub.4Ser).sub.n wherein n is an integer from 1 to 5; (d) a natural cleavage site comprising from one to about ten amino acids; (e) a self-cleaving amino acid sequence; (f) an intracellular trafficking sequence; or (g) any combination thereof. 13. The chimeric nucleic acid molecule of claim 1, wherein two or more of the HER2 antigenic peptides of the fusion protein are separated by a spacer comprising a (Gly.sub.4Ser).sub.n, wherein n is an integer from 1 to 5. 14. The chimeric nucleic acid molecule of claim 1, wherein the encoded fusion protein comprises an amino acid cleavage sequence amino-terminal to one or more of the encoded polypeptide components of the fusion protein, wherein the amino acid cleavage sequence comprises a 2A peptide from porcine teschovirus-1 (P2A), equine rhinitis A virus (E2A), Thosea asigna virus (T2A), or foot-and-mouth disease virus (F2A). 15. The chimeric nucleic acid molecule of claim 1, wherein the encoded fusion protein comprises a secretion signal amino acid sequence, a membrane localization amino acid sequence, an endosome targeting sequence, a dendritic cell targeting amino acid sequence, or any combination thereof. 16. The chimeric nucleic acid molecule of claim 1, wherein each encoded HER2 antigenic peptide of the fusion protein has: (a) at least 90% amino acid sequence identity to any one of SEQ ID NOS.:121-135; (b) an amino acid sequence of SEQ ID NOS.:121-135; (c) at least 90% amino acid sequence identity to any one of SEQ ID NOS.:117-120; (d) an amino acid sequence of SEQ ID NOS.:117-120; (e) at least 90% amino acid sequence identity to any one of SEQ ID NOS.:117-135; (f) an amino acid sequence of SEQ ID NOS.:117-135; or (g) any one of (a)-(f) further comprising from one to about five spacer amino acids on the N-terminus, C-terminus or both of one or more of each HER2 antigenic peptide of the fusion protein. 17. The chimeric nucleic acid molecule of claim 16, wherein the encoded fusion protein encoding any one or more of SEQ ID NOS.:117-135 further comprises a secretion signal amino acid sequence, a membrane localization amino acid sequence, an endosome targeting sequence, a dendritic cell targeting amino acid sequence, or any combination thereof. 18. The chimeric nucleic acid molecule of claim 16, wherein the encoded fusion protein encoding any one or more of SEQ ID NOS.:117-120 comprises: (a) a VSVG signal amino acid sequence as encoded by the polynucleotide of SEQ ID NO.:43 that is operably linked in frame to and disposed between the MTI sequence and the nucleic acid molecule encoding the fusion protein, optionally comprising a nucleic acid molecule encoding an amino acid cleavage sequence operably linked in frame to and disposed between the MTI sequence and the nucleic acid molecule encoding the VSVG signal amino acid sequence; (b) a VSVG trafficking amino acid sequence as encoded by the polynucleotide of SEQ ID NO.:47 or 48 that is operably linked in frame to the MTI sequence; (c) a VSVG membrane localization amino acid sequence as encoded by nucleotides 457 to 516 of SEQ ID NO.:57 that is operably linked in frame to the MTI sequence; (d) a VSVG trafficking amino acid sequence and membrane localization amino acid sequence as encoded by the polynucleotide of SEQ ID NO.:57 that is operably linked in frame to the MTI sequence; or (e) any one of (a)-(d) further comprising a dendritic cell targeting amino acid sequence as encoded by the polynucleotide of SEQ ID NO.:45; (f) any one of (a) or (c)-(e) further comprising an intracellular trafficking sequence. 19. The chimeric nucleic acid molecule of claim 1, wherein the encoded fusion protein comprises a polypeptide having at least 90% sequence identity with any one of the polypeptides set forth in SEQ ID NOS.:115 or 116; or wherein the encoded fusion protein comprises a polypeptide having at least 90% sequence identity with any one of the polypeptides set forth in SEQ ID NOS.:138, 140, 142-144, 146-148 or 150. 20. The chimeric nucleic acid molecule of claim 1, wherein the chimeric nucleic acid molecule comprises: (a) an mRNA molecule; (b) a DNA molecule; or (c) a DNA or RNA molecule contained in a vector and operably linked to an expression control sequence. 21. The chimeric nucleic acid molecule of claim 20, wherein the vector of subpart (c) comprises a plasmid vector or a viral vector. 22. The chimeric nucleic acid molecule of claim 21, wherein the vector comprises a viral vector selected from a rhabdoviral, adenoviral, herpesviral, poxviral, or retroviral vector. 23. A composition, comprising a chimeric nucleic acid molecule of claim 1 and a therapeutically acceptable carrier or excipient. 24. A method of eliciting an immune response, comprising administering to a human subject a therapeutically effective amount of a chimeric nucleic acid molecule, wherein the chimeric nucleic acid molecule comprises a multiplex translation initiation (MTI) sequence comprising from two to about five translation initiation sites operatively linked in frame to a nucleic acid molecule encoding a fusion protein comprising from two to about ten human epidermal growth factor receptor 2 (HER2) antigenic peptides, wherein at least one of the MTI translation initiation sites is a non-AUG translation initiation site and the MTI allows the production of more than one mole of fusion protein per mole of mRNA, thereby eliciting an immune response against one or more of the HER2 antigenic peptides. 25. The method of claim 24, wherein the elicited immune response comprises a cellular immune response that treats a HER2-associated cancer. 26. The method of claim 24, further comprising administering an effective amount of an antigenic peptide immunization composition comprising at least one HER2 antigenic peptide. 27. The method of claim 26, wherein: (a) the chimeric nucleic acid molecule and the antigenic peptide immunization compositions are administered simultaneously; (b) the chimeric nucleic acid molecule and the antigenic peptide immunization compositions are administered sequentially; (c) the chimeric nucleic acid molecule is administered from 1 hour to 8 weeks after the antigenic peptide immunization composition; (d) the antigenic peptide immunization composition is administered from 1 hour to 8 weeks after the chimeric nucleic acid molecule; or (e) any one of subparts (a) to (d) wherein the chimeric nucleic acid molecule encodes one or more of the same HER2 antigenic peptides of the antigenic peptide composition. 28. The method of claim 27, further comprising one or more additional administrations of an effective amount of the antigenic peptide immunization composition and/or the chimeric nucleic acid molecule after the first administration of the antigenic peptide immunization composition and/or the chimeric nucleic acid molecule. 29. The method of claim 24, further comprising administering an adjunctive therapy selected from the group consisting of surgery, chemotherapy, radiation therapy, antibody therapy, immunosuppressive therapy, and any combination thereof. 30. The method of claim 24, further comprising administering an adjunctive therapy selected from the group consisting of cyclophosphamide, trastuzumab, anti-PD1, anti-PDL1, anti-CTLA4, and any combination thereof. 31. The method of claim 24, wherein the MTI comprises one, two, three, or four non-AUG translation initiation sites. 32. The method of claim 31, wherein the non-AUG translation initiation sites are CUG translation initiation sites. 33. The method of claim 32, wherein the MTI comprises an AUG translation initiation site downstream of the CUG translation initiation sites. 34. The method of claim 24, wherein the MTI comprises (a) a nucleic acid molecule encoding one or two nuclear localization domains located downstream of two or three CUG translation initiation sites and upstream of an AUG translation initiation site, or (b) two or three CUG translation initiation sites upstream of a nucleic acid molecule encoding one or two nuclear localization domains and no AUG translation initiation site. 35. The method of claim 24, wherein the MTI comprises a 5'-portion of a human FGF2 gene, wherein the 5'-portion of the human FGF2 gene contains an AUG translation initiation site and about 123 nucleotides to about 385 nucleotides upstream of the AUG translation initiation site that is in frame with the nucleic acid molecule encoding the fusion protein. 36. The method of claim 35, wherein the MTI further comprises from about 15 nucleotides to about 45 nucleotides downstream of the AUG translation initiation site. 37. The method of claim 35, wherein the 5'-portion of the human FGF2 gene encodes a polypeptide having at least 90% sequence identity to any one of the amino acid sequences set forth in SEQ ID NOS.:8-12, or encodes a polypeptide as set forth in any one of SEQ ID NOS.:8-12. 38. The method of claim 24, wherein the MTI sequence has at least 90% sequence identity to a nucleotide sequence as set forth in any one of SEQ ID NOS.:1-6, 95, or 96. 39. The method of claim 24, wherein the encoded fusion protein comprises from two to about five different or same antigenic HER2 peptides, or the encoded fusion protein comprises five different antigenic HER2 peptides. 40. The method of claim 24, wherein one or more of the antigenic peptides are an HLA Class I antigenic HER2 peptide, an HLA Class II antigenic HER2 peptide, an HLA Class II antigenic HER2 peptide comprising an embedded HLA Class I antigenic HER2 peptide, or any combination thereof. 41. The method of claim 24, wherein one or more of the encoded HER2 antigenic peptides of the fusion protein comprise on the N-terminus and/or C-terminus: (a) from one to about ten junction amino acids; (b) a spacer comprising from two to about 35 amino acids; (c) a spacer comprising a (Gly.sub.4Ser).sub.n wherein n is an integer from 1 to 5; (d) a natural cleavage site comprising from one to about ten amino acids; (e) a self-cleaving amino acid sequence; (f) an intracellular trafficking sequence; or (g) any combination thereof. 42. The method of claim 24, wherein two or more of the HER2 antigenic peptides of the fusion protein are separated by a spacer comprising a (Gly.sub.4Ser).sub.n, wherein n is an integer from 1 to 5. 43. The method of claim 24, wherein the encoded fusion protein comprises an amino acid cleavage sequence amino-terminal to one or more of the encoded polypeptide components of the fusion protein, wherein the amino acid cleavage sequence comprises a 2A peptide from porcine teschovirus-1 (P2A), equine rhinitis A virus (E2A), Thosea asigna virus (T2A), or foot-and-mouth disease virus (F2A). 44. The method of claim 24, wherein the encoded fusion protein comprises a secretion signal amino acid sequence, a membrane localization amino acid sequence, an endosome targeting sequence, a dendritic cell targeting amino acid sequence, or any combination thereof. 45. The method of claim 24, wherein each encoded HER2 antigenic peptide of the fusion protein has: (a) at least 90% amino acid sequence identity to any one of SEQ ID NOS.:121-135; (b) an amino acid sequence of SEQ ID NOS.:121-135; (c) at least 90% amino acid sequence identity to any one of SEQ ID NOS.:117-120; (d) an amino acid sequence of SEQ ID NOS.:117-120; (e) at least 90% amino acid sequence identity to any one of SEQ ID NOS.:117-135; (f) an amino acid sequence of SEQ ID NOS.:117-135; or (g) any one of (a)-(f) further comprising from one to about five spacer amino acids on the N-terminus, C-terminus or both of one or more of each HER2 antigenic peptide of the fusion protein. 46. The method of claim 45, wherein the encoded fusion protein encoding any one or more of SEQ ID NOS.:117-135 further comprises a secretion signal amino acid sequence, a membrane localization amino acid sequence, a dendritic cell targeting amino acid sequence, or any combination thereof. 47. The method of claim 45, wherein the encoded fusion protein encoding any one or more of SEQ ID NOS.:117-120 comprises: (a) a VSVG signal amino acid sequence as encoded by the polynucleotide of SEQ ID NO.:43 that is operably linked in frame to and disposed between the MTI sequence and the nucleic acid molecule encoding the fusion protein, optionally comprising a nucleic acid molecule encoding an amino acid cleavage sequence operably linked in frame to and disposed between the MTI sequence and the nucleic acid molecule encoding the VSVG signal amino acid sequence; (b) a VSVG trafficking amino acid sequence as encoded by the polynucleotide of SEQ ID NO.:47 or 48 that is operably linked in frame to the MTI sequence; (c) a VSVG membrane localization amino acid sequence as encoded by nucleotides 457 to 516 of SEQ ID NO.:57 that is operably linked in frame to the MTI sequence; (d) a VSVG trafficking amino acid sequence and membrane localization amino acid sequence as encoded by the polynucleotide of SEQ ID NO.:57 that is operably linked in frame to the MTI sequence; or (e) any one of (a)-(d) further comprising a dendritic cell targeting amino acid sequence as encoded by the polynucleotide of SEQ ID NO.:45; (f) any one of (a) or (c)-(e) further comprising an intracellular trafficking sequence. 48. The method of claim 24, wherein the encoded fusion protein comprises a polypeptide having at least 90% sequence identity with any one of the polypeptides set forth in SEQ ID NOS.:115 or 116; or wherein the encoded fusion protein comprises a polypeptide having at least 90% sequence identity with any one of the polypeptides set forth in SEQ ID NOS.:138, 140, 142-144, 146-148 or 150. 49. The method of claim 24, wherein the chimeric nucleic acid molecule comprises: (a) an mRNA molecule; (b) a DNA molecule; or (c) a DNA or RNA molecule contained in a vector and operably linked to an expression control sequence. 50. The method of claim 49, wherein the vector of subpart (c) comprises a plasmid vector or a viral vector. 51. The method of claim 50, wherein the vector comprises a viral vector selected from a rhabdoviral, adenoviral, herpesviral, poxviral, or retroviral vector. 52. The method of claim 24, wherein the chimeric nucleic acid molecule is formulated as a composition comprising a therapeutically acceptable carrier or excipient. 53. The method of claim 24, comprising contacting the chimeric nucleic acid molecule with an immune cell ex vivo before administration, and administering to the human subject a population of immune cells containing the chimeric nucleic acid molecule.

Details for Patent 9,655,956

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Genentech, Inc.	HERCEPTIN	trastuzumab	For Injection	103792	09/25/1998		2039-02-26
Genentech, Inc.	HERCEPTIN	trastuzumab	For Injection	103792	02/10/2017		2039-02-26
Genentech, Inc.	HERCEPTIN HYLECTA	trastuzumab and hyaluronidase-oysk	Injection	761106	02/28/2019		2039-02-26